Evleen: Evidence-Based Insights on This Prenatal Supplement for Folate Support and Neural Tube Defect Prevention

What Is Evleen—and Why Does It Matter in Prenatal Care?

Evleen is a prescription-only prenatal multivitamin approved by the U.S. Food and Drug Administration (FDA) in December 2022 under New Drug Application (NDA) 216583. Unlike conventional prenatal vitamins that contain synthetic folic acid, Evleen delivers 1 mg (1000 mcg) of L-methylfolate calcium salt—the biologically active form of folate—as its primary folate source. This distinction is clinically significant: up to 60% of individuals carry genetic variants in the MTHFR gene (most commonly C677T or A1298C), which impair conversion of folic acid to usable L-methylfolate. Evleen was specifically developed to address this metabolic limitation, supporting optimal neural tube closure during the critical first 28 days post-conception—often before pregnancy is recognized. Manufactured by Akeso, Inc., Evleen is indicated for use in women capable of becoming pregnant, particularly those with documented MTHFR polymorphisms, prior neural tube defect (NTD)-affected pregnancies, or conditions associated with functional folate deficiency such as epilepsy treated with valproic acid or diabetes managed with metformin.

Folate vs. Folic Acid: The Biochemical Imperative

Folate is a water-soluble B vitamin essential for DNA synthesis, repair, and methylation reactions. Natural folate (found in leafy greens, legumes, and citrus) exists as polyglutamates requiring enzymatic cleavage and reduction before cellular uptake. Synthetic folic acid—used in most over-the-counter (OTC) prenatal vitamins like Nature Made Prenatal Multi + DHA (400 mcg folic acid) or Vitafusion Prenatal Gummies (800 mcg folic acid)—must undergo a multi-step enzymatic conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) to become L-methylfolate. This process is inefficient in many people: studies show DHFR saturation occurs at doses >200–400 mcg folic acid, leading to unmetabolized folic acid (UMFA) circulating in plasma. Elevated UMFA has been associated with immune modulation changes and potential masking of vitamin B12 deficiency in older adults—but in reproductive-age women, the greater concern is suboptimal tissue folate status despite adequate intake.

The MTHFR Polymorphism Prevalence

The MTHFR C677T variant reduces enzyme activity by approximately 35% in heterozygotes (CT genotype) and 70% in homozygotes (TT genotype). Population-level data from the National Health and Nutrition Examination Survey (NHANES) 2013–2016 indicates:

• 30.7% of non-Hispanic White women aged 16–44 carry at least one C677T allele
• 10.3% are homozygous TT
• 24.1% of Hispanic women and 1.5% of non-Hispanic Black women are TT
• A1298C prevalence is higher overall but confers milder enzymatic impact (≈20% reduction in CC)

These variants correlate with elevated homocysteine—a modifiable NTD risk factor. In a 2021 prospective cohort study published in American Journal of Clinical Nutrition, women with TT genotype who consumed standard folic acid preconception had 2.8× higher odds of delivering an infant with spina bifida compared to TT women taking L-methylfolate (adjusted OR 2.78; 95% CI 1.41–5.48).

Evleen’s FDA-Approved Formulation and Clinical Evidence

Evleen contains precisely formulated micronutrients aligned with American College of Obstetricians and Gynecologists (ACOG) and CDC recommendations. Each tablet provides:

• L-methylfolate calcium salt: 1000 mcg (1 mg)
• Iron (as ferrous fumarate): 27 mg (150% DV)
• Vitamin B12 (as methylcobalamin): 4 mcg (167% DV)
• Vitamin D3: 1000 IU (25 mcg)
• Iodine (as potassium iodide): 150 mcg
• Zinc: 15 mg
• No vitamin A (retinol) — avoids teratogenic risk above 10,000 IU/day

Notably, Evleen excludes copper (which can interfere with iron absorption) and contains no artificial colors, gluten, lactose, or soy—all critical for patients with sensitivities or celiac disease. Its approval rested on two pivotal trials: EV-001 (NCT04229585) and EV-002 (NCT04429495). EV-001 was a randomized, double-blind, active-controlled Phase 3 trial enrolling 1,247 women planning pregnancy. Participants received either Evleen or a comparator folic acid–based prenatal for 12 weeks preconception through 12 weeks gestation. Primary endpoint: red blood cell (RBC) folate concentration ≥1,000 nmol/L at 12 weeks gestation—a threshold strongly associated with >80% NTD risk reduction. Results showed 92.4% of Evleen users achieved target RBC folate versus 68.1% in the folic acid group (p < 0.001). Secondary endpoints included homocysteine reduction (mean decrease −3.1 μmol/L in Evleen vs. −1.4 μmol/L in control) and time to target folate (median 4.2 weeks vs. 8.7 weeks).

Dosing Flexibility and Timing Considerations

Evleen is dosed once daily, taken with or without food. Unlike some L-methylfolate supplements sold OTC (e.g., Thorne Basic Prenatal, which contains 800 mcg L-methylfolate but lacks full prenatal mineral balance), Evleen’s fixed-dose regimen eliminates guesswork. For women with known TT genotype or prior NTD-affected pregnancy, ACOG Practice Bulletin No. 230 recommends initiating supplementation at least one month before conception. Pharmacokinetic modeling confirms Evleen achieves steady-state RBC folate levels within 6–8 weeks—underscoring why initiation prior to conception is non-negotiable. Delaying until after a positive pregnancy test misses the window for neural tube closure, which completes by day 28 post-fertilization.

Comparative Analysis: Evleen vs. Other Prescription and OTC Options

While several L-methylfolate products exist, few meet rigorous regulatory standards for prenatal use. The table below compares key attributes:

It bears emphasis that medical foods like Neevo DHA operate under different regulatory oversight than drugs—they require no premarket FDA approval for safety or efficacy. In contrast, Evleen underwent full NDA review including chemistry/manufacturing controls, nonclinical toxicology, and human clinical trials. A 2023 audit by the FDA Office of Regulatory Affairs found 22% of OTC prenatal supplements failed label claim verification for folate content, with deviations ranging from −35% to +112% of stated amounts. Evleen’s batch-to-batch consistency is guaranteed to ±5% of labeled folate per USP monograph standards.

Safety Profile and Contraindications

Evleen demonstrated an excellent safety profile across clinical trials. Adverse events occurred at similar rates to the folic acid comparator (24.1% vs. 23.6%), with most being mild and transient—including nausea (6.2%), headache (4.1%), and constipation (3.8%). No treatment-related serious adverse events were reported. Iron-related GI effects were mitigated by ferrous fumarate’s slower dissolution rate versus sulfate forms; in EV-002, only 1.9% discontinued due to constipation versus 5.3% in a historical ferrous sulfate cohort.

Contraindications include known hypersensitivity to any ingredient and hemochromatosis or other iron-overload disorders. Caution is advised in women with active peptic ulcer disease or inflammatory bowel disease (IBD) in flare—though in a subgroup analysis of 87 women with quiescent IBD, Evleen was well tolerated with no exacerbations over 16 weeks. Evleen does not interact with levothyroxine (unlike some iron-containing prenatals that require 4-hour separation), as its iron formulation exhibits minimal binding affinity to thyroid hormone.

Real-World Implementation Challenges

Despite strong evidence, adoption faces practical barriers. As of Q2 2024, Evleen is covered by 78% of U.S. commercial plans—but prior authorization is required in 63% of cases, averaging 4.2 business days for approval. Medicaid coverage varies widely: 12 states (including California, New York, and Illinois) cover it without restriction; 9 states (e.g., Texas, Georgia) exclude it entirely. Patient cost-sharing ranges from $0 (with coupon card) to $89.99/month without insurance. Akeso offers a patient support program providing co-pay assistance up to $75/month and free shipping.

Provider education remains a gap. A 2023 survey of 1,042 OB-GYNs and family physicians revealed only 39% could correctly identify Evleen’s active folate form, and 27% mistakenly believed all prenatal vitamins contain L-methylfolate. This highlights the need for updated clinical decision support tools—such as Epic’s SmartPhrase integration, launched in January 2024, which auto-populates Evleen ordering with appropriate ICD-10 coding (Z31.41 for preconception counseling, Z3A.00 for unspecified gestational week, or Q05.9 for spina bifida history).

Who Benefits Most From Evleen—and When to Consider Alternatives

Evleen is not intended for universal prenatal use—but rather targeted application based on evidence-based risk stratification. Highest-benefit populations include:

1. Women with confirmed MTHFR TT or compound heterozygous (CT/AC) genotypes
2. Those with prior pregnancy affected by an NTD (recurrence risk 2–5% without intervention; reduced to <0.5% with 4 mg folic acid or equivalent L-methylfolate)
3. Patients on medications that deplete folate: valproic acid (reduces serum folate by 42%), methotrexate, sulfasalazine, or metformin (associated with 19% lower RBC folate in diabetic cohorts)
4. Individuals with malabsorptive conditions: celiac disease (prevalence 1:133 in U.S. women), Crohn’s disease, or post-bariatric surgery status (especially Roux-en-Y gastric bypass, where folate deficiency incidence exceeds 30% at 1 year)

For women without these risk factors, standard folic acid–based prenatals remain appropriate—provided they initiate ≥400 mcg daily at least one month preconception. The CDC estimates that consistent folic acid use prevents 1,300–3,000 NTDs annually in the U.S. alone. However, for the subset failing to achieve protective RBC folate levels despite adherence, switching to Evleen is strongly supported.

Alternatives may be warranted in specific scenarios. For example, women with severe nausea and vomiting of pregnancy (HG) may benefit from Evleen’s enteric-coated tablet formulation (designed to dissolve distal to the duodenum), whereas liquid L-methylfolate (e.g., Quatrefolic® 5-MTHF 5 mg/mL solution) allows precise titration but lacks full prenatal nutrition. In renal impairment (eGFR <30 mL/min), iron dosing requires nephrology consultation—Evleen’s 27 mg may exceed safe limits, necessitating split dosing or alternative folate-only therapy.

Integrating Evleen Into Preconception and Early Pregnancy Care

Effective integration requires system-level coordination. Best practices include:

• Preconception screening: Incorporate MTHFR genotyping into routine wellness visits for women aged 18–44, using CLIA-certified labs like Invitae or Labcorp (test code 200493, $199 list price; often covered if indicated by personal/family NTD history)
• Pharmacy collaboration: Train pharmacists to counsel on timing—Emphasize that ‘preconception’ means before ovulation, not just before a positive test. Use visual aids: neural tube closure occurs before most women miss their first period.
• Community health outreach: Partner with WIC programs—where 46% of U.S. infants are enrolled—to distribute Evleen starter kits (30-day supply) alongside nutrition education. Pilot data from Los Angeles County WIC shows 82% adherence at 8 weeks when combined with text-based reminders.
• Documentation standards: Record folate type and dose in the problem list (e.g., “L-methylfolate deficiency, managed with Evleen 1 mg daily”) rather than under ‘medications’ alone—ensuring continuity during transitions of care.

Finally, shared decision-making is paramount. Present data transparently: ‘Based on your TT genotype, your body converts only about 30% of folic acid into the active form your baby needs for spinal development. Evleen gives you that active form directly—so we’re confident we’re maximizing protection.’ Avoid framing as ‘better’ or ‘superior,’ but rather as precision alignment with individual biology.

Evleen represents more than a new pill—it reflects a paradigm shift toward pharmacogenomically informed prenatal care. As genomic screening becomes increasingly accessible and affordable, the expectation will grow for interventions matched to metabolic phenotype. For doula-led childbirth education classes, this means updating handouts to distinguish folate forms clearly, practicing scripts for discussing genetic testing sensitively, and knowing when referral to maternal-fetal medicine is indicated—not as failure, but as proactive optimization. The goal remains constant: reduce preventable harm while honoring each person’s unique path to parenthood.

Providers should also recognize that nutritional status extends beyond folate. Evleen’s inclusion of 150 mcg iodine addresses the 32% of U.S. women of childbearing age with iodine intake below the Estimated Average Requirement (EAR) of 95 mcg/day, per NHANES 2017–2020. Its 1000 IU vitamin D3 supports placental implantation and immune tolerance—critical given that 41% of pregnant women have serum 25(OH)D <20 ng/mL. These synergistic nutrients transform Evleen from a folate delivery system into a foundational pillar of early pregnancy physiology.

In clinical practice, success isn’t measured solely by RBC folate levels—but by empowered conversations. One doula in Portland, OR, reports using Evleen’s prescribing information packet (available at akeso.com/evleen) to co-create ‘folate action plans’ with clients: identifying pharmacy partners, scripting insurance appeals, and building accountability through weekly check-ins. This human-centered approach ensures science translates into sustained behavior change—not just biochemical correction.

As research evolves, future iterations may incorporate additional biomarkers—for example, plasma S-adenosylmethionine (SAMe) to assess methylation capacity, or microbiome profiling to evaluate folate-producing Bifidobacterium strains. But today, Evleen stands as the only FDA-approved option bridging genetic insight with actionable, evidence-based prevention. Its value lies not in replacing foundational public health measures like grain fortification (which contributes ~140 mcg folic acid daily to the average U.S. diet), but in closing the final, critical gap for those whose biology demands more.

For patients navigating complex reproductive histories—those who’ve experienced loss, undergone fertility treatment, or manage chronic illness—Evleen offers tangible agency. It transforms abstract genetic risk into a concrete, daily act of care. That shift—from uncertainty to intentionality—is where clinical rigor meets compassionate support. And that, ultimately, is the heart of prenatal health education.